China RNA vaccine developer raises $42m
Therorna, a China-based biotech company specializing in vaccines and drugs based on circular RNA technology, has raised USD 42m in Series A funding.
The round was led by MSA Capital and an undisclosed industrial investment firm, with participation from Sherpa Healthcare Partners and 3H Health Investment. Existing investors Quan Capital and Cenova Capital...
More on Greater China
Latest News
ADIA commits $83m to India's Aditya Birla Health Insurance
Abu Dhabi Investment Authority (ADIA) has agreed to invest INR 6.6bn (USD 83.5m) in India’s Aditya Birla Health Insurance (ADBHI) for a 10% stake.
Bain targets $102m Japan advertising take-private
Bain Capital has won board approval from Net Marketing, a Tokyo-listed online advertising and media management business, for a take-private that values the company at approximately JPY 13.6bn (USD 102m).
China's Insilico Medicine gets another $35m
Insilico Medicine, a China-based artificial intelligence-driven drug discovery company, has closed the second tranche of its Series D round on USD 35m, with Prosperity7 Ventures taking the lead.
Singapore crypto risk platform extends Series A to $24m
Singapore’s Merkle Science, a predictive crypto analytics platform, has raised USD 24m in Series A funding led by K3 Ventures, Darrow Holdings, and Beco Capital.